EUCTR2009-017647-34-GB进行中（未招募）1 期
Effect of minocycline and amoxicillin administration on the prevalence of antibiotic resistant bacteria and on the indigenous oral, faecal, cutaneous and nasal microbiotas. - ANTIRESDEV
Helperby Therapeutics0 个研究点目标入组 42 人开始时间: 2010年3月18日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Men and women aged between 18 and 40 years.
- •2.Following verbal & written information about the trial, the subject has signed & dated informed consent before any study related activity was carried out.
- •3.Subject legally competent and able to communicate effectively with the study personnel
- •4.Normal finding in the medical history and physical examination, unless the investigator considers an abnormality to be clinically irrelevant.
- •5.Male or female subjects who are using a medically acceptable method of contraception or of non-childbearing potential (i.e., surgically sterile-bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to dosing or naturally postmenopausal for at least one year with a Screening FSH level = 40 mIU/L). A negative serum pregnancy test is required at Screening for females.
- •Female subjects
- •Female subjects of childbearing potential must use medically acceptable methods of contraception from the time of the first administration of the study medication until 3 months following administration of the last application of study medication. Acceptable methods include:
- •Oral contraceptives (combination oestrogen/progesterone pills), injectable progesterone or sub-dermal implants and a barrier method {condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository}:
- •A documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and the use of a barrier method {condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository};
- •Medically prescribed topically-applied transdermal contraceptive patch and a barrier method {condom or occlusive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository};
- •Documented tubal ligation (female sterilisation). In addition, a barrier method {condom or occlu-sive cap (diaphragm or cervical/vault caps) used with spermicidal foam/gel/film/cream/suppository} should also be used;
- •Double barrier method: Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
- •Abstinence.
- •Male subjects
- •Male subjects must use medically acceptable methods of contraception if their female partners are pregnant from the time of the first administration of the study medication until 3 months following administration of the last application of study medication. Acceptable methods include:
- •If the subject has undergone surgical sterilisation (vasectomy with documentation of azoosper-mia) a condom with spermicidal foam/gel/film/cream/suppository should also be used.
- •Use acceptable methods of contraception if the male subject’s partner could become pregnant from the time of the first administration of study medication until 3 months following administration of the last application of study medication. The acceptable methods of contraception are as follows:
- •Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
- •Surgical sterilisation (vasectomy with documentation of azoospermia) and
排除标准
- •1.Regular use of medication, except contraceptive, vitamin tablets, treatment with antimicrobial agents within the 3 months preceding the study,
- •Use of antibiotics for 4 weeks prior to the study drug application or use of concomitant systemic or topical antibiotics,
- •Systemic treatment with immunosuppressive drugs e.g. cyclosporine, azathioprine or oral Subject Restrictions.
- •2.Participation in a trial with another investigational drug within the 3 months preceding the study
- •3.Present or residual gastrointestinal, renal insufficiency or hepatic disorder
- •4.Abnormal pathology of nasal passages
- •5.Any clinically significant allergy or drug intolerance
- •6.Active hay fever, on-going cold/flu symptoms, including rhinitis at screening (visit 2)
- •7.Any medical history of renal insufficiency or hepatic disorder or other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs
- •8.history of hypersensitivity to beta-lactams or tetracycline
- •9.pregnant or breast-feeding women
- •10.Subjects known or suspected of not being able to comply with trial protocol (e.g. alcoholism, drug dependency, or psychological state). History of regular alcohol consumption exceeding an average weekly intake of alcohol greater than 21 units for female and 28 units for male. One unit is equivalent to a half-pint of beer or one measure of spirits or one glass of wine.
- •11.Subjects with known or suspected immunodeficiency.
研究者
相似试验
招募中
3 期
Investigating the effect of amoxicillin in reducing infection after impacted wisdom tooth surgeryIRCT20200705048014N2Bandare-abbas University of Medical Sciences40
已完成
不适用
Effect of Amoxicillin and Metronidazole in recovery of chronic periodontitisIRCT2014020816141N2Hamadan Medical Sciences University30
尚未招募
4 期
A study to compare effect of amoxicillin & clavulinic acid and Moxifloxacin after removal of wisdom tooth.CTRI/2019/11/022107Department of Pharmacology
招募中
3 期
Comparison the amoxicillin and pantoprazole regimen with quadruple regimen for Helicobacter pylori eradicatioIRCT20211019052812N1Ahvaz University of Medical Sciences166
进行中（未招募）
1 期
Impact on the intestinal flora during antibiotic treatmentEffects of phenoximetylpenicillin, amoxicillin and amoxicillin-clavulanic acid on the gut microbiota of healthy volunteersEUCTR2019-000953-30-SEppsala University Hospital120